Championing novel science
Dr. Vikas Mohan Sharma announces FDA fast-track designation for BI 1358894 as potential treatment for Borderline Personality Disorder.
Szukaj
Nasz Kodeks postępowania
Globalny Kodeks Postępowania firmy Boehringer Ingelheim
SIRPα Cancer Immunology Research
Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
A beginner’s guide to fighting off cat parasites
Prof. Donato Traversa explains the risk of multiparasitic infections and/or infestations in cats
Behind the Lab
Delve behind the lab to see how our Retinal Health scientists are spearheading research into novel therapeutics to treat retinopathies.
Nerandomilast osiągnął pierwszorzędowy punkt końcowy w badaniu FIBRONEER™-IPF
Nerandomilast osiągnął pierwszorzędowy punkt końcowy w badaniu FIBRONEER™-IPF
Europe needs a vibrant research eco-system
At this week's EFPIA Days in Brussels, stakeholders will discuss how to re-establish a research-friendly eco-system in Europe.
Covid19 relief program Ghana Cowtribe parasiticides
Boehringer Ingelheim and Cowtribe are kicking off a vital relief initiative in Ghana.
Bigger role in ensuring food security
As the world population is projected to reach 9.8 billion in 2050, animal health becomes fundamental to ensure both animal well-being and global protein supply.
Our-position
Potential access to selected medications for appropriate patients with serious, life-threatening diseases unable to participate in a clinical trial
Pierwsza połowa 2024 roku
Pierwsza połowa 2024 roku
“Rapid progress towards clinical candidates”
Boehringer Ingelheim forms a joint venture to create the next generation of antimicrobials.
Historia Boehringer Ingelheim w latach 1948-1990,
Historia Boehringer Ingelheim w latach 1948-1990, z kamieniami milowymi
Empagliflozyna zatwierdzona do leczenia osób dorosłych z przewlekłą chorobą nerek w UE
Empagliflozyna zatwierdzona do leczenia osób dorosłych z przewlekłą chorobą nerek w UE